Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average rating of “Moderate Buy” from ...

Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putting its accelerated ...

Baird analyst Joel Beatty upgraded Amylyx (AMLX) to Outperform from Neutral with a price target of $11, up from $3. The firm has become more ...

Patient organisations have been celebrating the FDA approval yesterday of Amylyx' amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that ...

Amylyx Pharma (NASDAQ:AMLX) just reported results for the first quarter of 2024. Amylyx Pharma reported earnings per share of -12 cents. This was below the analyst estimate for EPS of -1 cent.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the 7th Annual Evercore ISI ...

As previously reported, BofA analyst Charlie Yang upgraded Amylyx (AMLX) to Buy from Neutral with a price target of $10, up from $4.20, based on the firm’s view of avexitide, a drug being ...

Baird analyst Joel Beatty upgraded Amylyx (AMLX) to Outperform from Neutral with a price target of $11, up from $3. The firm has become more favorable on avexitide, a GLP-1 receptor antagonist ...

We plan to engage with the FDA and other stakeholders to inform our Phase 3 program in Wolfram,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “Additionally, we are on track to ...

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) had its target price lifted by analysts at HC Wainwright from $8.00 to $12.00 in a report issued on Friday,Benzinga reports.The brokerage ...

Looking ahead, revenue is expected to decline by 79% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 10%.